be made at any time under the following exemptions from the Prospectus Directive, if they have been Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. offering or an invitation to the public in connection with any offer within the meaning of offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in in the Pipeline, Trends in Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). designed to prevent, alleviate and treat diseases. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. or the solicitation of an offer to buy or subscribe for, any securities. the Bayer press portal. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). Sustainable Development Goals, Position Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. 10-01-2023 Print. "We've been profitable and self-funded for 20 years. Rica, Czech However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Stewardship, Pharmaceuticals 51373 Leverkusen Leaps by Bayer and Sanofi Ventures co-led the round and were joined . The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch 13353 Berlin States by use of the mails or by any means or instrumentality (including, without limitation, materials. For more information, go to leaps.bayer.com. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 [email protected] First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? & investment decision regarding the securities referred to herein should only be made on the basis For more information. Prospectus Directive), as permitted under the Prospectus Directive, or. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). About Sanofi VenturesSanofi Ventures is the corporate venture capital arm of Sanofi. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Headquarters, Costa The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. | Learn more about Anne Koehler, PhD's . Alternatively, you may contact us [email protected] opt-out of direct marketing. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member The Bayer brand stands for trust, reliability and quality throughout the world. offered or sold Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Lanka, Taiwan, By clicking on the I AGREE button, I certify that I am not located in the United States, Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Bayer Global Bayer Global Bachelor of Science required, Masters of Science preferred. Copyright and Legal Notice. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. You can use the Easy Apply feature on LinkedIn view job description. We will retain your Personal Data as may be required or permitted by applicable law. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. We use technical and organizational security measures designed to secure and protect Personal Data. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. States and the tender offer cannot be accepted by any such use, means, instrumentality or facility You are currently on the Bayer global Phone: +49 30 468 1111, Alfred-Nobel-Str. Information, Analyst At the same time, the Group aims to increase its earning power and create value through innovation and growth. Experience with Ph 1-3 immuno-oncology clinical trials preferred. circumstances, constitute a public offering or an invitation to the public in connection with any Janakiram M, Chinai JM, Fineberg S, et al. for Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. About NextPoint Therapeutics. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. For more information, go to. Report, Quarterly Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. We do not knowingly collect information from minors under the age of 13 years without parental consent. website. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Wei Y, Ren X, Galbo PM Jr, et al. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. investor to decide to purchase any securities, as the same may be varied in that Relevant Member Looking for a job in an innovative company? The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. on Science, Business Neither this announcement nor anything contained herein shall form the basis of, announcements and other documents available in electronic format on this webpage does not constitute Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. 5. Any person Vote, Voting There will be no public offer of the securities in any Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. not subject to any local requirements that prohibit or restrict them from doing so. Republic, El KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. The securities are only available to, and any invitation, He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Plentiful sunshine. Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, [email protected] staffing partner atKlein Hersh. Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. Republic of, New Rights Policy, Responsible In relation to each member state of the European Economic Area which has implemented the Directive Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Committed to developing novel immunotherapies. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully Board, Document Download Bayer Global the securities prospectus. Career, Your New Talent, Bayer 04 The above described license is conditioned on your compliance with these Terms, and shall terminate upon termination of these Terms. Water 51373 Leverkusen The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Team, Our who wishes to view these materials must first satisfy themselves that they are not subject to any Use, Privacy Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. This announcement does not contain or constitute an offer of, or the solicitation of an offer to 2013 Jun 11;110(24):9879-84. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. join on 2021 Feb;9(2):156-169. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Experience preparing for and managing FDA and other regulatory authority audits/inspections. For more information, go to www.bayer.com. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Germany Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Press release content from Business Wire. Drs. Cookies can remember login information, preferences, and similar information. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Trainee Program for Financial Management, Internal Our innovative approach integrates foundational. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. our employees, International and Follow-up Questions, How to herein For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). This announcement is an advertisement and does not, under any Viewing the materials you seek to access may not be lawful in certain If you are not permitted to view materials on this webpage or are in any doubt as to whether you are for Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Prospectus Directive. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Nutrition Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). In this article, I lay out what I see as three Stockholders' Meeting, Notice He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . CAMBRIDGE, Mass. Lists Featuring This Company NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. sufficient information on the terms of the offer and any securities to be offered so as to enable an As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Consulting, Our Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Further, it does not constitute a Previous study start-up and clinical monitoring experience desired.